Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.54 |
| ▸ | MERTK | Q12866 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639751 | 0.88 | AXL (0.70) | AXLEGFRAURKARETMET | |
| SCHEMBL468644 | 0.86 | AXL (0.61) | AXLEGFRAURKARETMET | |
| SCHEMBL467892 | 0.85 | AXL (0.52) | AXLEGFRAURKARETMET | |
| SCHEMBL1640474 | 0.84 | AXL (0.57) | AXLEGFRAURKARETMET | |
| SCHEMBL30090794 | 0.84 | AXL (0.57) | AXLEGFRAURKARETMET | |
| SCHEMBL467825 | 0.82 | AXL (0.77) | AXLEGFRAURKARETMET | |
| SCHEMBL467824 | 0.82 | AXL (0.77) | AXLEGFRAURKARETMET | |
| SCHEMBL30121612 | 0.82 | AXL (0.77) | AXLEGFRAURKARETMET | |
| SCHEMBL467813 | 0.82 | AXL (0.54) | AXLEGFRAURKARETMET | |
| SCHEMBL467922 | 0.82 | AXL (0.53) | AXLEGFRAURKARETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | claimed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2024-08-22 | — | — | US | disclosed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | disclosed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | disclosed |
| EP-4125908-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BerGenBio ASA (NO) | 2023-02-08 | — | — | EP | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
| US-20120264740-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8168636-B2 | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2010083465-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7709482-B2 | angiogenesis and/or cell proliferation, carcinoma, myeloid leukemia, endometriosis; inhibitors of the receptor protein tyrosine kinase; N3-(3-cyclopentyl-1,2,3,4,5,6-hexahydrobenzo[d]azocin-8-yl)-1-(6-fluoroquinazolin-4-yl)-1H-1,2,4-triazole-3,5-diamine | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885EGFR 42/4885AURKA 77/4885 |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | AXL, CD274, HAVCR2 | AXL 1/4885EGFR 45/4885AURKA 64/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | AXL 1/4885EGFR 55/4885AURKA 176/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | AXL 2/4885EGFR 81/4885AURKA 436/4885 |
| US-20100168416-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885EGFR 45/4885AURKA 572/4885 |
| US-20080188455-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885EGFR 45/4885AURKA 572/4885 |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885EGFR 45/4885AURKA 572/4885 |
| US-20120264740-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885EGFR 45/4885AURKA 572/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | AXL 3/4885EGFR 235/4885AURKA 120/4885 |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885EGFR 42/4885AURKA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.